NO931561L - APPLICATION OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATMENT OF INFLAMMATION AND SCARS - Google Patents

APPLICATION OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATMENT OF INFLAMMATION AND SCARS

Info

Publication number
NO931561L
NO931561L NO93931561A NO931561A NO931561L NO 931561 L NO931561 L NO 931561L NO 93931561 A NO93931561 A NO 93931561A NO 931561 A NO931561 A NO 931561A NO 931561 L NO931561 L NO 931561L
Authority
NO
Norway
Prior art keywords
treatment
inhibitors
scars
inflammation
plasminogen activators
Prior art date
Application number
NO93931561A
Other languages
Norwegian (no)
Other versions
NO931561D0 (en
Inventor
Eckhard Schueler
Juergen Roemisch
Eric-Paul Paques
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of NO931561D0 publication Critical patent/NO931561D0/en
Publication of NO931561L publication Critical patent/NO931561L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Inhibitorer av plasminogenaktivatorer, som urokinase, uPA eller tPA for intra- og post-operativ terapi, for behandling av skader samt for behandling og profylakse av betennelsessykdommer er beskrevet. Egnede inhibitorer er spesielt PAI-1 og PAI-2,Inhibitors of plasminogen activators, such as urokinase, uPA or tPA for intra- and post-operative therapy, for the treatment of injuries and for the treatment and prophylaxis of inflammatory diseases have been described. Suitable inhibitors are especially PAI-1 and PAI-2.

NO93931561A 1992-04-30 1993-04-29 APPLICATION OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATMENT OF INFLAMMATION AND SCARS NO931561L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4214215A DE4214215A1 (en) 1992-04-30 1992-04-30 USE OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATING INFLAMMATION

Publications (2)

Publication Number Publication Date
NO931561D0 NO931561D0 (en) 1993-04-29
NO931561L true NO931561L (en) 1993-11-01

Family

ID=6457814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93931561A NO931561L (en) 1992-04-30 1993-04-29 APPLICATION OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATMENT OF INFLAMMATION AND SCARS

Country Status (16)

Country Link
EP (1) EP0567816A1 (en)
JP (1) JPH069425A (en)
KR (1) KR930021179A (en)
CN (1) CN1080873A (en)
AU (1) AU3822993A (en)
CA (1) CA2095207A1 (en)
CZ (1) CZ76893A3 (en)
DE (1) DE4214215A1 (en)
HU (1) HUT65755A (en)
IL (1) IL105521A0 (en)
MX (1) MX9302519A (en)
NO (1) NO931561L (en)
PL (1) PL298748A1 (en)
SK (1) SK41593A3 (en)
UY (1) UY23572A1 (en)
ZA (1) ZA933023B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
GB2271507A (en) * 1992-09-04 1994-04-20 Summit Technology Ireland Bv Compositions containing plasmin activity inhibitors
CN1502331A (en) * 1993-07-19 2004-06-09 Ѫ�ܼ���ҩ�﹫˾ Antiangiogenic compositions and methods of use
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
IL138594A0 (en) * 1998-04-01 2001-10-31 Biotech Australia Pty Ltd Use of protease inhibitors for treating skin wounds
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
JP2002543143A (en) 1999-04-29 2002-12-17 イスタ・ファーマスーティカルズ・インコーポレイテッド Biochemical methods to eliminate corneal scarring, opacity and haze
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
JP3690720B2 (en) 1999-09-14 2005-08-31 インターナショナル・ビジネス・マシーンズ・コーポレーション Client server system, object pooling method, and storage medium
WO2001030379A2 (en) 1999-10-27 2001-05-03 Alexandra Lucas Compositions and methods for preventing and treating transplant rejection
JP2001247458A (en) * 2000-03-08 2001-09-11 Hamari Chemicals Ltd Antidiabetic agent containing zinc tranexamate compound
JP2004509171A (en) 2000-09-29 2004-03-25 ゾーン、　ロバート　ズィー． Method and composition for treating inflammation and immune response
PT1328213E (en) 2000-10-16 2005-10-31 Conor Medsystems Inc EXPANSIVE MEDICAL DEVICE FOR THE ADMINISTRATION OF A BENEFICIAL AGENT
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
US6964680B2 (en) 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
AT500019B1 (en) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm USE IN VITRO OF THE TRANSCRIPTION FACTOR NAK-1 OR NAK-1 REGULATED GENES FOR THE DIAGNOSIS OF INFLAMMATORY AND MALIGNIC DISEASES
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US7169179B2 (en) 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20110130338A1 (en) * 2008-01-21 2011-06-02 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases
CN109925507A (en) * 2017-12-15 2019-06-25 深圳瑞健生命科学研究院有限公司 A kind of method and drug prevented or treat osteoarthritis
CN119044501A (en) * 2024-07-17 2024-11-29 浙江大学 Application of PAI-2 tear concentration detection reagent in preparation of kit for identifying ocular surface injury or disease caused by atmospheric fine particulate matters
CN118557734B (en) * 2024-07-24 2024-11-22 中山大学中山眼科中心 Application of SERPINB2 inhibitor in the preparation of drugs for treating wet age-related macular degeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829523A1 (en) * 1988-08-31 1990-03-01 Behringwerke Ag USE OF PLASMINOGEN ACTIVATOR INHIBITOR (PAI-2) FOR IMMUNE SUPPRESSION
WO1991009124A1 (en) * 1989-12-20 1991-06-27 Biotech Australia Pty. Limited Variants of pai-2
EP0451130A3 (en) * 1990-04-05 1992-08-05 Baltimore Biotech, Inc. Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization

Also Published As

Publication number Publication date
CN1080873A (en) 1994-01-19
MX9302519A (en) 1993-10-01
HUT65755A (en) 1994-07-28
CA2095207A1 (en) 1993-10-31
UY23572A1 (en) 1993-05-04
DE4214215A1 (en) 1993-11-04
SK41593A3 (en) 1993-11-10
JPH069425A (en) 1994-01-18
KR930021179A (en) 1993-11-22
NO931561D0 (en) 1993-04-29
ZA933023B (en) 1994-10-31
AU3822993A (en) 1993-11-04
PL298748A1 (en) 1993-12-27
CZ76893A3 (en) 1994-01-19
HU9301272D0 (en) 1993-07-28
EP0567816A1 (en) 1993-11-03
IL105521A0 (en) 1993-08-18

Similar Documents

Publication Publication Date Title
MX9302519A (en) EMPLOYMENT OF PLASMINOGEN ACTIVATOR INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AND WOUNDS.
BG98902A (en) IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKIN INHIBITORS
DK0719154T3 (en) Activated factor VIII as a therapeutic agent and method for treating factor VIII deficiency
ATE277612T1 (en) ARYL UREA DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATORY DISEASES
Bunning et al. Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes
ATE275583T1 (en) KALLIKREINHIBITING ßKUNITZ-DOMAINESS PROTEINS AND DERIVATIVES THEREOF
NO961888D0 (en) Peptidyl compounds and their therapeutic use as inhibitors of metal proteinases
ATE310087T1 (en) PLASMA KALLIKREIN INHIBITORS OF THE KUNITZ TYPE
PT705100E (en) THERAPEUTIC SUBSTITUTED GUANIDINS
NO922634L (en) AZAOKSINDOL-DERIVATIVES
ZA945425B (en) 2-amino-4-phenyl-4-oxo-butyric acid derivatives
ATE38036T1 (en) BENZOTHIOPHENE DERIVATIVES AS BRONCHODILATORS.
DE69333639D1 (en) Trypsininhibitoren
FI955721A7 (en) For the expression of urokinase-type plasminogen activator inhibitors
MXPA94009086A (en) Therapeutic substituted guanidines.
GR3020355T3 (en) Aminosulfonyl urea acat inhibitors
NO983295L (en) Control of healing process
DE68916958D1 (en) TOPICALLY APPLIED GOLD ORGANO COMPLEX.
EE9800263A (en) Use of carbonic anhydrase inhibitors for the treatment of macular edema
AU3496295A (en) 2-substituted-4h-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement clr protease for the treatment of inflammatory processes
AU2861389A (en) Disubstituted pyridines
ES2139674T3 (en) METHOD TO TREAT THE SYMPTOMATOLOGY OF PREMENSTRUAL SYNDROME WITH VITAMIN D OR VITAMIN D AND CALCIUM.
NO962259D0 (en) Use of dimeticone for the treatment of aphthae and stomatitis
IL111501A0 (en) Pharmaceutical compositions comprising lys-plasminogen and tissue plasminogen activator (t-PA) for the treatment of coronary thrombosis
WO2024015478A3 (en) Combination therapies of wdr5 inhibitors and pd-1 inhibitors